m****g
发帖数: 530 | 1 ROCKVILLE, Md., March 31, 2010-FDA notified healthcare professionals and
patients that it is evaluating data
from a long-term clinical trial called Stalevo Reduction in Dyskinesia
Evaluation - Parkinson's Disease
(STRIDE-PD), that may suggest that patients taking Stalevo may be at an
increased risk for developing
prostate cancer. Other controlled clinical trials evaluating Stalevo or
Comtan (entacapone) did not find an
increased risk of prostate cancer. FDA is still reviewing the available
infor |
|
